SCHEMBL4451993

SCHEMBL4451993

Oc1c(Cl)cc(Cl)c2cc(Cl)cnc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.55
MEN1 O00255 5/20 0.55
HTT P42858 5/20 0.55
KMT2A Q03164 5/20 0.55
SMN1; SMN2 Q16637 5/20 0.55
ALDH1A1 P00352 4/20 0.55
KDM4E B2RXH2 4/20 0.55
TDP1 Q9NUW8 4/20 0.55
HSP90AA1 P07900 4/20 0.55
CYP3A4 P08684 4/20 0.55
LMNA P02545 4/20 0.55
OPRK1 P41145 3/20 0.55
MMP14 P50281 3/20 0.55
ALOX15 P16050 3/20 0.55
ALOX12 P18054 3/20 0.55
SLC6A2 P23975 3/20 0.55
TP53 P04637 2/20 0.55
HTR1A P08908 2/20 0.55
ALOX15B O15296 1/20 0.55
NR1I2 O75469 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4448881 0.81 MAPT (0.51) MAPTMEN1HTTKMT2ASMN1; SMN2
Bromide SCHEMBL4451997 0.79 MAPT (0.50) MAPTMEN1HTTKMT2ASMN1; SMN2
SCHEMBL28884188 0.74 ALK (0.40) TDP1LMNARECQLHIF1AL3MBTL1
SCHEMBL29888687 0.74 ALK (0.40) TDP1LMNARECQLHIF1AL3MBTL1
SCHEMBL16459993 0.71 IDO1 (0.36) KMT2ASMN1; SMN2ALDH1A1LMNATSHR
SCHEMBL25328672 0.71 MAPT (0.51) MAPTMEN1HTTKMT2ASMN1; SMN2
Chloroxine SCHEMBL29389908 0.71 KDM4E (1.00) MAPTMEN1HTTKMT2ASMN1; SMN2
Chloroxine SCHEMBL29399997 0.71 KDM4E (1.00) MAPTMEN1HTTKMT2ASMN1; SMN2
Chloroxine SCHEMBL3350 0.71 KDM4E (1.00) MAPTMEN1HTTKMT2ASMN1; SMN2
Chloroxine SCHEMBL231205 0.69 KDM4E (0.96) MAPTMEN1HTTKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6362339-B1 ELECTROLUMINESCENCE 3M INNOVATIVE PROPERTIES COMPANY 2002-03-26 US claimed
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression SIERRA SCIENCES, INC. (US) 2023-07-18 US disclosed
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression SIERRA SCIENCES, INC. (US) 2023-07-18 US disclosed
US-9302993-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2016-04-05 US disclosed
US-9302993-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2016-04-05 US disclosed
US-9302993-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2016-04-05 US disclosed
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-11-26 US disclosed
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-11-26 US disclosed
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-11-26 US disclosed
US-9169211-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2015-10-27 US disclosed
EP-1539700-A4 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LTD (AU) 2006-06-28 EP disclosed
US-20060089380-A1 8-Hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LTD. (AU) 2006-04-27 US disclosed
EP-1539700-A1 8-HYDROXY QUINOLINE DERIVATIVES Prana Biotechnology Ltd (AU) 2005-06-15 EP disclosed
WO-2004007461-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2004-01-22 WO disclosed
WO-2004007461-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2004-01-22 WO disclosed
EP-1218345-B1 METHOD OF MAKING METAL 8-QUINOLINOLATO COMPLEXES 3M INNOVATIVE PROPERTIES CO (US) 2003-04-02 EP disclosed
EP-1218345-A1 METHOD OF MAKING METAL 8-QUINOLINOLATO COMPLEXES 3M Innovative Properties Company (US) 2002-07-03 EP disclosed
US-20020040143-A1 Method of making metal 8-quinolinolato complexes 3M INNOVATIVE PROPERTIES COMPANY 2002-04-04 US disclosed
US-6362339-B1 ELECTROLUMINESCENCE 3M INNOVATIVE PROPERTIES COMPANY 2002-03-26 US disclosed
WO-2001025211-A1 METHOD OF MAKING METAL 8-QUINOLINOLATO COMPLEXES 3M INNOVATIVE PROPERTIES COMPANY (US) 2001-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PARK7, COQ8A, NLN MAPT 170/4885MEN1 1871/4885HTT 15/4885
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression TERT, TERF2, RNGTT MAPT 2505/4885MEN1 3550/4885HTT 178/4885
US-20020040143-A1 Method of making metal 8-quinolinolato complexes COQ8A, SDHA, LDHA MAPT 424/4885MEN1 523/4885HTT 856/4885
US-20060089380-A1 8-Hydroxy quinoline derivatives PARK7, HTT, SNCA MAPT 122/4885MEN1 3123/4885HTT 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.